The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | G | Genito urinary system and sex hormones | |
| 2 | G03 | Sex hormones and modulators of the genital system | |
| 3 | G03A | Hormonal contraceptives for systemic use | |
| 4 | G03AA | Progestogens and estrogens, fixed combinations | |
| 5 | G03AA18 |
| Active Ingredient | Description | |
|---|---|---|
| Drospirenone and Estetrol |
Estetrol demonstrates anti-gonadotropic activity characterised by a dose-dependent decrease in both serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels. The progestogen drospirenone possesses progestagenic, antigonadotropic, antiandrogenic and mild antimineralocorticoid properties and has no oestrogenic, glucocorticoid or antiglucocorticoid activity. These properties are pharmacologically similar to the natural hormone progesterone. The contraceptive effect of drospirenone/estetrol is based on the interaction of various factors, the most important of which is inhibition of ovulation. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DROVELIS Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
